MICRORNA-122 AS A BIOLOGICAL MARKER OF CHRONIC VIRAL HEPATITIS C

2020 ◽  
pp. 72-75
Author(s):  
O. P. Shevchenko-Makarenko ◽  
L. R. Shostakovych-Koretska ◽  
V. E. Dosenko ◽  
T. I. Drevytska
Keyword(s):  
Gene Expression ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Biological Marker ◽  
Chronic Viral Hepatitis ◽  
Expression Level ◽  
Healthy Individuals ◽  
Hcv Genotype ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

New epigenetic markers are being studied in various countries around the world to diagnose, predict, and treat the patients with chronic viral hepatitis C. Epigenetics is currently studying the hereditary changes in gene expression or phenotype that are not related to the changes in DNA sequence. One field of epigenetics is the expression of RNA that does not encode a protein, namely miRNA, which is a molecule 18−22 nucleotides in length that plays a crucial role in regulating gene expression. Circulating miRNAs are a new genetic material that can be isolated from a patient's blood. The expression level of a particular miRNA has different biological and clinical effects. By means of its determination in various miRNAs it is possible to predict development of diseases. In order to study the baseline expression of miRNA−122 in patients with chronic viral hepatitis C with the first HCV genotype, 74 patients were examined. Diagnosis and monitoring of the patients was performed according to the local protocols and bioethical standards. The level of miRNA−122 expression in patients with chronic viral hepatitis C with the first HCV genotype was established by reverse transcription. Studies show that the level of miRNA−122 expression in the patients with HCV and healthy individuals showed significant variability. The obtained data indicate that the expression level of miRNA−122 in patients is 29 times higher than in healthy individuals at p = 0.0001 (U; Z). This can be an additional biomarker as an index of the presence of chronic viral hepatitis C and can be further used in practice. Therefore, the high level of miRNA−122 expression in subjects (≥ 8.771 rel. units (Log10 miR−122 ≥ 0.939 rel. units)) may be the basis for further screening of patients for HCV infection. The prospects of using this index, which will allow to personalize the diagnosis and treatment tactics for patients, that, in turn, will contribute to the implementation of the WHO global strategy for the elimination of viral hepatitis. Key words: chronic viral hepatitis C, miRNA−122, elimination of viral hepatitis, biological marker.

CLINICAL SIGNIFICANCE OF EXPRESSION RATE OF MIRNA-29A IN PATIENTS WITH CHRONIC VIRAL HEPATITIS

2020 ◽  
pp. 83-86
Author(s):  
O. P. Shevchenko-Makarenko
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Antiviral Therapy ◽  
Rapid Development ◽  
Chronic Viral Hepatitis ◽  
Previous Experience ◽  
Expression Level ◽  
Control Group ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

Chronic viral hepatitis C is an urgent problem of hepatology. During the rapid development of epigenetics, small molecules, namely microRNA and microRNA−29a are actively studied in liver pathology. For this purpose, the level of miRNA−29a expression was studied in 74 patients having chronic viral hepatitis C with the first HCV genotype. Aberrant hyperexpression of miRNA−29a in the patients, the ability to differentiate the patients with chronic viral hepatitis C with sensitivity and specificity of the model of ROC analysis Se = 67.57 % and Sp = 90.91 %, DE = 79.24 % compared with healthy individuals. The expression of miRNA−29a was studied in the patients with chronic viral hepatitis C, who had a poor experience with antiviral therapy with interferon−containing protocols. The expression level of miRNA−29a was determined according to the manufacturer's protocol using the TaqMan® microRNA reverse transcription kit (Applied Biosystems, USA).The mean level of miRNA−29a expression in the patients with chronic viral hepatitis C (Me) and in groups of patients was assessed depending on previous experience of antiviral therapy. Aberrant hyperexpression of miRNA−29a was detected in the patients with chronic viral hepatitis C. In naive patients the level of miRNA−29a expression was 1.65 (1.27; 2.28) conventional units and in the patients with failed antiviral therapy according to regimens containing interferon was 1.64 (0.79; 2.20) conventional units compared with the control group (p = 0.002, H), which may reflect the potential mechanism of persistence of HCV infection. Thus, the expression level of miRNA−29a can be an additional biomarker in the pathogenesis of chronic viral hepatitis C, which can be used in the monitoring and treatment of patients, become the basis for prescribing the patients more effective protocols of targeted antiviral drugs and allow personification of treatment tactics. Key words: chronic viral hepatitis C, previous experience of antiviral therapy, miRNA−29a, aberrant hyperexpression.

scholarly journals THE ROLE OF GALECTIN-9 IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND ITS CONNECTION WITH THE TYPE OF THERAPY, THE DEGREE OF FIBROSIS, CLINICAL, LABORATORY, AUTOIMMUNE AND INTEGRATIVE INDICATORS

2021 ◽  
Vol 74 (5) ◽  
pp. 1180-1188
Author(s):  
Mykola D. Chemych ◽  
Anastasiia G. Lishnevska
Keyword(s):  
Platelet Count ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Clinical Laboratory ◽  
Chronic Viral Hepatitis ◽  
Healthy Individuals ◽  
Non Invasive ◽  
Group I ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

The aim: To establish the dependence of the concentration of galectin-9(CGal-9) in the serum of patients with chronic viral hepatitis C (CVHC) on the type of antiviral therapy (AVT), clinical-laboratory, autoimmune and integrative parameters, non-invasive methods of assessing the degree of fibrosis. Materials and methods: CGal-9 in serum were determined in 68 patients with CVHC and 20 healthy individuals, and clinical-laboratory and integrative parameters, noninvasive methods for assessing the degree of fibrosis were studied. Results:There were three groups: baseline (I), pegylated interferon (PEG-IFN) with ribavirin (II), velpatasvir with sofosbuvir (III). In pations from group I, compared with healthy people, CGal-9 was 1.7 times higher (p <0.05); in patients from group II it was 4.2 times higher (p<0.05); in patients from group III it did not differ from healthy individuals. All patients had a directly proportional correlation between CGal-9 and the frequency of splenomegaly detection; in patients who did not receive AVT, directly proportional – with De Ritis ratio, non-invasive methods of liver fibrosis, inversely proportional – with platelet count (p<0,05). There was a higher probability of positive indicators of antinuclear antibodies (ANA) at 12 weeks of treatment with PEG-IFN and ribavirin, with higher CGal-9 at 4 weeks of AVT (p<0,05). Conclusions: Correlations between CGal-9 and the frequency of splenomegaly detection, platelet count, De Ritis ratio, degree of lever fibrosis in correlation with METAVIR, APRI, FIB-4, ANA, NI were determined. The possibility of predicting the occurrence of splenomegaly, liver cirrhosis and positive ANA in patients with CVHC has been proven.

scholarly journals Assessment of adherence to chronic viral hepatitis C treatment in Romania: an open, single center, prospective study

2016 ◽  
Vol 2 (2) ◽  
pp. 59-68
Author(s):  
Anca Streinu-Cercel ◽  
Maria-Magdalena Moțoi ◽  
Alina Cristina Neguț ◽  
Luminița Bradu ◽  
Daniela Manolache ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Prospective Study ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Single Center ◽  
Hepatitis C Treatment ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany

2018 ◽  
Vol 35 (4) ◽  
pp. 661-666 ◽  
Author(s):  
Cristina Stasi ◽  
Caterina Silvestri ◽  
Roberto Berni ◽  
Maurizia Rossana Brunetto ◽  
Anna Linda Zignego ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Clinical Data ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

Chronic viral hepatitis C. Approach to therapy

2021 ◽  
Vol 87 (1) ◽  
pp. 37-41
Author(s):  
T. Ye. Makarova ◽  
◽  
N.N. Dudareva ◽  
N.N. Poletaeva ◽  
E.A. Medvedeva ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
High Incidence ◽  
Chronic Viral Hepatitis C

The problem of chronic viral hepatitis C currently remains relevant due to the high incidence, frequent outcomes in liver cirrhosis, high disability of the population, and expensive treatment. The article discusses timely approaches to the treatment of chronic viral hepatitis C, using interferon-free therapy regimens.

Antiviral therapy of liver cirrhosis in the outcome of chronic viral hepatitis C

2021 ◽  
pp. 89-97
Author(s):  
ANARKAN SHABOLOTOVNA TASHPOLOTOVA ◽  
GULMIRA SAIBILDAEVNA SURANBAEVA ◽  
MYSKAL MAMAZIAEVNA ABDIKERIMOVA ◽  
ALTYNAI BORUBAEVNA MYRZAKULOVA ◽  
ANARA SHAMSHIDINOVNA DJUMAGULOVA ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Antiviral Therapy ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C
Sign in / Sign up

Export Citation Format

Share Document